Imbruvica

Active Ingredient(s): Ibrutinib
FDA Approved: * November 13, 2013
Pharm Company: * PHARMACYCLICS
Category: Cancer

Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.[4][5]... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
2 Discussions

Dosage List

Imbruvica ibr140mg
Imbruvica (Ibrutinib 140 mg)
NDC: 57962-140
Labeler:
Pharmacyclics, Inc
Imbruvica 70 mg/ml Oral Suspension
NDC: 57962-007
Labeler:
Pharmacyclics LLC
Imbruvica 140 mg Oral Tablet, Film Coated
NDC: 57962-014
Labeler:
Pharmacyclics LLC
Imbruvica 70 mg Oral Capsule
NDC: 57962-070
Labeler:
Pharmacyclics LLC
Imbruvica 280 mg Oral Tablet, Film Coated
NDC: 57962-280
Labeler:
Pharmacyclics LLC
Imbruvica 420 mg Oral Tablet, Film Coated
NDC: 57962-420
Labeler:
Pharmacyclics LLC
Imbruvica 560 mg Oral Tablet, Film Coated
NDC: 57962-560
Labeler:
Pharmacyclics LLC

Popular Topics

side effects with imbruvica

I have CLL/SLL with 11q deletion, recently I have been having several problems and cannot find the right information on ...

4 REPLIES